Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BTK | Q06187 | 1/20 | 0.78 |
| ▸ | GAA | P10253 | 2/20 | 0.53 |
| ▸ | CA1 | P00915 | 1/20 | 0.52 |
| ▸ | CA2 | P00918 | 1/20 | 0.52 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.51 |
| ▸ | CTSK | P43235 | 2/20 | 0.50 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.47 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.47 |
| ▸ | RELA | Q04206 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 1/20 | 0.47 |
| ▸ | MAOB | P27338 | 1/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.45 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7212396 | 1.00 | BTK (0.78) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL7210932 | 1.00 | BTK (0.78) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL14502820 | 1.00 | BTK (0.78) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL22957939 | 0.93 | BTK (0.69) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL20737119 | 0.93 | BTK (0.69) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL369297 | 0.92 | BTK (0.72) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL25234757 | 0.92 | BTK (0.68) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL16070792 | 0.92 | BTK (0.68) | BTKGAACA1CA2EPHX1 | |
| SCHEMBL21912379 | 0.92 | BTK (0.68) | BTKGAACA1CA2EPHX1 | |
| Methyl Alcohol SCHEMBL9686628 | 0.90 | BTK (0.70) | BTKGAACA1CA2EPHX1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8350042-B2 | Antiviral compounds for the treatment of HCV infection | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2013-01-08 | — | — | US | disclosed |
| US-20110003855-A1 | ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF HCV INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-06 | — | — | US | disclosed |
| US-20110003855-A1 | ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF HCV INFECTION | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-06 | — | — | US | disclosed |
| EP-0765313-B1 | N,N'-BIS(QUINOLIN-4-YL)-DIAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIMALARIALS | HOFFMANN LA ROCHE (CH) | 2003-08-20 | — | — | EP | disclosed |
| US-5736557-A | MICROBIOCIDE EFFECTIVE AGAINST CHLOROQUINE-RESISTANT AND CHLOROQUINE-SENSITIVE STRAINS OF PLASMODIUM FALCIPARUM | HOFFMAN-LA ROCHE, INC. (US) | 1998-04-07 | — | — | US | disclosed |
| EP-0765313-A1 | N,N'-BIS(QUINOLIN-4-YL)-DIAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIMALARIALS | F. HOFFMANN-LA ROCHE AG (CH) | 1997-04-02 | — | — | EP | disclosed |
| WO-1995035287-A1 | N,N'-BIS(QUINOLIN-4-YL)-DIAMINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS ANTIMALARIALS | F.HOFFMANN-LA ROCHE AG (CH) | 1995-12-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110003855-A1 | ANTIVIRAL COMPOUNDS FOR THE TREATMENT OF HCV INFECTION | EIF2AK2, HAVCR2, GOT1 | BTK 3076/4885GAA 133/4885CA1 4781/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.